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AbstrAct
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human solid 
tumor and current treatments are ineffective in increasing patients’ survival. Thus, the 
development of new therapeutic approaches for ATC is needed. We have previously 
shown that the oncolytic adenovirus dl922-947 induces ATC cell death in vitro and 
tumor regression in vivo. However, the impact of dl922-947 on the pro-tumorigenic 
ATC microenvironment is still unknown. Since viruses are able to regulate cytokine and 
chemokine production from infected cells, we sought to investigate whether dl922-947 
virotherapy has such effect on ATC cells, thereby modulating ATC microenvironment. 
dl922-947 decreased IL-8/CXCL8 and MCP-1/CCL2 production by the ATC cell lines 
8505-c and BHT101-5. These results correlated with dl922-947-mediated reduction of 
NF-κB p65 binding to IL8 promoter in 8505-c and BHT101-5 cells and CCL2 promoter 
in 8505-c cells. IL-8 stimulates cancer cell proliferation, survival and invasion, and 
also angiogenesis. dl922-947-mediated reduction of IL-8 impaired ATC cell motility in 
vitro and ATC-induced angiogenesis in vitro and in vivo. We also show that dl922-947-
mediated reduction of the monocyte-attracting chemokine CCL2 decreased monocyte 
chemotaxis in vitro and tumor macrophage density in vivo. Interestingly, dl922-
947 treatment induced the switch of tumor macrophages toward a pro-inflammatory 
M1 phenotype, likely by increasing the expression of the pro-inflammatory cytokine 
interferon-γ. Altogether, we demonstrate that dl922-947 treatment re-shape the 
pro-tumorigenic ATC microenvironment by modulating cancer-cell intrinsic factors 
and the immune response. An in-depth knowledge of dl922-947-mediated effects on 
ATC microenvironment may help to refine ATC virotherapy in the context of cancer 
immunotherapy.
IntroductIon
Tumorigenesis is a multistep process that involves 
cancer cell-intrinsic alterations and complex interactions 
with tumor stroma and infiltrating immune cells [1, 2]. 
Although therapeutic strategies aimed to target specific 
features of this process have proved to be effective 
for cancer treatment, their curative potential is often 
hampered by the development of a variety of resistance 
mechanisms. These involve acquisition of alternative 
strategies to restore the feature targeted by the treatment 
or reliance on other mechanisms. Indeed, cancer cell-
extrinsic factors provided by the tumor microenvironment 
may mediate resistance to cytotoxic therapies. Thus, it is 
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conceivable that strategies aimed at co-targeting several 
tumor-promoting mechanisms (e.g. cancer cell-intrinsic 
features and the tumor microenvironment) could optimize 
effectiveness and reduce therapeutic escape [3].
Oncolytic viruses (OVs) are non-pathogenic viral 
strains or viral mutants that selectively replicate in and 
kill tumor cells without causing harm to normal cells [4]. 
The efficacy and safety of OVs has been demonstrated 
in clinical studies with encouraging results [5]. Recently, 
The FDA has approved the first oncolytic viral therapy, 
Talimogene laherparepvec (T-VEC), to treat surgically 
unresectable skin and lymph node lesions in patients with 
advanced melanoma [6].
The mechanism of action of OVs has long been 
thought to be solely dependent on direct tumor cell killing. 
A growing body of evidence points to the immune system 
as having a critical role in determining the efficacy of 
virotherapy [7-9]. Indeed, OVs may break the tolerogenic 
tumor microenvironment and induce a long-lasting CD8 
T cell-mediated anti-tumor response, thereby acting as 
vaccines [7]. In certain cases, a robust immune-dependent 
anti-tumor response was also elicited independently 
of viral oncolysis and replication [10]. Based on this 
evidence, several viral strains have been engineered to 
express factors (e.g. cytokines, chemokines and membrane 
receptors) that boost the anti-tumor immune response of 
which several have already shown promising results in 
clinical trials [11-16]. Taken together, evidence obtained 
so far suggests that a complex interaction between OV 
replication and the response of both tumor and immune 
cells to OV infection eventually determines the outcome 
of virotherapy. 
Anaplastic thyroid carcinoma (ATC) is one of the 
deadliest human solid tumors: although it accounts for 
less than 3% of all thyroid cancers, ATC is responsible 
for up to 50% of the annual mortality associated with 
thyroid tumors [17]. ATC treatment consists of surgery 
combined with radiation and chemotherapy. However, 
this treatment is often palliative as death usually occurs 
within 6 months from diagnosis, commonly caused by 
tracheal obstruction [18]. Several novel approaches have 
been tested for the treatment of ATC, including gene 
therapy [19, 20] and oncolytic virotherapy [21]. Our 
group has extensively evaluated the oncolytic adenovirus 
dl922-947 for the treatment of ATC. dl922-947 is a second 
generation adenoviral mutant bearing a 24-bp deletion in 
E1A-Conserved Region 2 [21]. This region binds to and 
inactivates pRb, dissociating the pRb-E2F complex and 
driving S phase entry and viral replication. The mutant 
E1A protein encoded by dl922-947 is unable to bind pRb, 
thereby the virus cannot induce S phase entry in normal 
cells. Nonetheless, dl922-947 replicates in cells with an 
aberrant G1-S checkpoint, which is a feature of almost 
90% of human cancers [22]. In several experimental 
neoplastic models, including ATC, dl922-947 treatment, 
alone or in combination with molecularly-targeted drugs 
or ionizing radiations, can induce cancer cell death and 
tumor regression [23-30]. Although these studies were 
aimed to demonstrate synergistic effects of the combined 
treatments, we also observed an anti-angiogenic effect of 
the virus [29]. It is still unclear whether and how dl922-
947 virotherapy modulates ATC microenvironment. 
Understanding the modulation of ATC microenvironment 
by dl922-947 treatment and the contribution to the anti-
tumoral activity will be instrumental to develop more 
effective therapies.
ATC is markedly infiltrated by immune cells, namely 
macrophages [31, 32], which are likely to play a role in 
ATC development and progression. Tumor-associated 
macrophages (TAMs) may differentiate from peripheral 
blood monocytes recruited in a MCP-1/CCL2-dependent 
manner (hereafter CCL2) [33]. ATC cells express high 
levels of the enzyme indoleamine 2,3-dioxygenase 1 
(IDO1) that catalyzes the conversion of amino acid 
tryptophan to the immunosuppressive molecule kynureine 
[34]. In addition, ATC cells produce the chemokine IL-8/
CXCL8 (hereafter IL-8) that is involved in several aspects 
of tumor biology, namely cell proliferation, cell survival, 
epithelial-to-mesenchymal transition, stemness, and also 
angiogenesis [35-38]. 
Virus-infected cells activate an antiviral response 
aimed at blocking viral replication. The cellular antiviral 
response involves the production of type I and type III 
interferons (IFNs) and the modulation of cytokine and 
chemokine production. On the other hand, viruses have 
evolved several mechanisms to counteract the cellular 
antiviral mechanisms, e.g. by modulating the activity of 
transcription factors involved in the production of cytokine 
and chemokines [39, 40]. We hypothesized that dl922-
947 virotherapy of ATC cells modulate the production of 
cytokines and chemokines, leading to modification of the 
tumor microenvironment.
In the present study we show that dl922-947 
treatment reduces IL-8 and CCL2 production by ATC 
cell lines via displacement of the transcription factor NF-
κB p65 from IL8 and CCL2 promoters. Furthermore, we 
provide evidence that dl922-947-induced reduction of 
IL-8 and CCL2 production correlates with impaired tumor 
angiogenesis and decreased macrophage density in vitro 
and in vivo.
results
dl922-947 reduces Il-8 and ccl2 production by 
Atc cell lines
The cellular response to viral infections involves the 
production of IFNs and the modulation of cytokines and 
chemokines release. Therefore, we analyzed by ELISA 
whether dl922-947 treatment of the ATC cell lines 8505-
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c and BHT101-5 modulates the expression of cytokines, 
chemokines and angiogenic factors. We could not detect 
TNF or IL-10 secretion in any of the tested conditions 
(data not shown), while VEGF-A production was not 
significantly modified by dl922-947 compared to the 
replication-defective adenovirus AdGFP (Supplementary 
Figure 1). Interestingly, both cell lines produced high 
levels of IL-8 and CCL2, which were reduced upon 
treatment with dl922-947 but not AdGFP (Figure 1, left 
panels). The latter results were confirmed by Real-Time 
PCR analysis of mRNA levels (Figure 1, right panels). In 
addition, we observed the same pattern of IL-8 and CCL2 
secretion when the concentrations of these chemokines 
were normalized on the total cellular protein content to 
account for dl922-947-induced cell death (Supplementary 
Figure 2A).
In several cell types, the constitutive- or stimuli (e.g. 
PMA or TNF)-induced expression of IL-8 is negatively 
regulated by IFNβ at the transcriptional level [41-43]. 
Furthermore, virus-infected cells produce IFNβ as 
Figure 1: Il-8 and ccl2 secretion and expression upon dl922-947 treatment. 8505-c and BHT101-5 cells were treated with 
dl922-947 or the non-replicating adenovirus AdGFP (5 an 1 pfu/cell for both viruses, respectively). 48 hours after infection IL-8 and CCL2 
secretion (left panels) and expression (right panels) were assessed by ELISA on cell-free supernatants and Real-Time PCR, respectively. The 
results are the mean of three independent experiments ±SEM. One-way ANOVA and Tuckey post-test: *p<0.05; **p<0.01; ***p<0.001.
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part of their antiviral response program [40]. Thus, we 
investigated whether IFNβ was involved in the dl922-
947-dependent reduction of IL-8 production by acting in 
an autocrine/paracrine manner. IFNβ treatment did not 
reduce IL-8 production (Supplementary Figure 2B), nor 
IFNβ secretion could be detected by dl922-947-infected 
ATC cell lines (data not shown).
Il-8 and ccl2 reduction is associated with 
NF-κB p65 displacement from IL8 and CCL2 
promoters
The expression of IL8 and CCL2 genes is regulated 
by NF-κB p65 (hereafter p65) nuclear localization and 
binding to cis-regulatory elements in IL8 and CCL2 
promoters [44-46]. dl922-947 reduced p65 binding to IL8 
Figure 2: p65 localization and binding to IL8 and CCL2 promoters after dl922-947 treatment. A. 8505-c and BHT101-5 
cells were treated with dl922-947 (5 or 1 pfu/mL, respectively). After 24 hours, p65 binding to IL8 (upper panels) and CCL2 (lower panels) 
promoters was assessed by chromatin immunoprecipitation (ChIP) assay. For each experimental condition, p65 binding is expressed as 
fold enrichment over the non-specific binding (IgG) control. The results are the mean of three independent experiments ±SEM. One-way 
ANOVA and Tuckey post-test: ***p<0.001. b. 8505-c and BHT101-5 cells were treated for 24 hours with dl922-947 (5 and 1 pfu/cell, 
respectively). Cellular fractionation was performed to isolate nuclear and cytosolic fraction. Lysates were probed with p65 antibody, as well 
as Lamin A/C and GAPDH antibodies to verify the purity of the preparations. The blots are representative of three independent experiments.
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(in BHT101-5 and 8505-c cells) and CCL2 (in 8505-c) 
promoters, as assessed by chromatin immunoprecipitation 
(ChIP) assay (Figure 2A), without affecting total p65 
protein levels (Supplementary Figure 3A). Cellular 
fractionation showed that dl922-947 treatment reduced 
p65 nuclear localization in BHT101-5 (Figure 2B). This 
effect was not observed in 8505-c cells (Figure 2B), 
indicating an alternative mechanism of p65 modulation. 
Adenoviral proteins (e.g. E1A, E1B19K, E3) are 
known to interact with p65, impairing its activity [47-49]. 
In addition, p65 binds to E3 promoter and induces the 
expression of E3 proteins [50]. dl922-947 is completely 
deleted in E310.4K, E314.5K and E314.7K genes, whereas 
it has only a 24 bp deletion in the pRb-interacting region 
of E1A gene (E1AΔ24) [51]. To assess which adenoviral 
protein mediates the effects of dl922-947, we treated both 
cell lines with the E1B19K-deleted adenovirus Δ19K that 
express an intact form of E1A. The mutant Δ19K reduced 
IL8 mRNA expression (Supplementary Figure 3B), 
excluding E1B19K involvement in p65 modulation. Then, 
ATC cell lines were transfected with plasmids expressing 
E1A wild type (E1Awt) or a CR2-deleted form of E1A 
Figure 3: E1A-dependent and -independent modulation of IL8 and CCL2 gene expression. A. 8505-c and BHT101-5 
cells were transfected with wild type (E1Awt) or a mutated form (E1AΔ24) of the adenoviral protein E1A. 32 hours after transfection 
IL8 and CCL2 mRNA expression was evaluated by Real-Time PCR. The results are the mean of three independent experiments ±SEM. 
One-way ANOVA and Tuckey post-test: ***p<0.001. b. 8505-c and BHT101-5 cells were transfected with E1Awt or E1AΔ24 alone or 
co-transfected with p65. 32 hours after transfection E1A was immunoprecipitated and its binding to p65 was assessed by western blotting 
using an anti-p65 antibody. The levels of p65, E1A and α-tubulin in total cell lysates were included as input controls. A BHT101-5 cells 
only transfected with p65 was used as positive control (p65 +ve control). The blots are representative of three independent experiments.
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(E1AΔ24). The efficiency of transfection was confirmed 
by assessing E1A mRNA levels in transfected cells (data 
not shown). Transfection of E1Awt and E1AΔ24 reduced 
IL8 expression in 8505-c but not in BHT101-5 cells 
(Figure 3A). To evaluate a direct interaction between E1A 
and p65, protein extracts were immunoprecipitated using 
an anti-E1A antibody and the binding to p65 was assessed 
using an anti-p65 antibody. The interaction of E1Awt 
and E1AΔ24 with p65 was only observed in 8505-c cells 
(Figure 3B). Taken together, our data indicate that dl922-
947 reduces p65 binding to IL8 promoter through an E1A-
dependent mechanism in 8505-c cells or E1A-independent 
mechanisms that leads to reduced p65 nuclear localization 
in BHT101-5 cells.
We also evaluated p65 binding to CCL2 promoter 
upon dl922-947 treatment. In 8505-c cells dl922-947 
displaced p65 from the CCL2 promoter (Figure 2A). 
BHT101-5 did not show any constitutive binding of 
p65 to the CCL2 promoter (Figure 2A), likely due to 
an alternative regulation of CCL2 gene expression. 
In accordance with IL8 expression data, Δ19K 
treatment reduced CCL2 expression in both cell lines 
(Supplementary Figure 3B), while transfection of E1Awt 
and E1AΔ24 reduced CCL2 expression in 8505-c but not 
in BHT101-5 cells (Figure 3A).
To further validate our results we investigated 
the effects of dl922-947 treatment on IL-8 and CCL2 
production by the papillary thyroid carcinoma cell 
line TPC1. dl922-947 and Δ19K treatments reduced 
IL-8 and CCL2 production at mRNA and protein 
levels (Supplementary Figure 4A). In addition, Δ19K 
significantly reduceds both IL8 and CCL2 expression 
(Supplementary Figure 4B). These results correlated with 
p65 displacement from IL8 and CCL2 promoters upon 
dl922-947 treatment (Supplementary Figure 5A). Similar 
to the results obtained with 8505-c cells, transfection 
of TPC1 cells with E1Awt or E1AΔ24 was sufficient to 
reduce IL8 and CCL2 mRNA expression (Supplementary 
Figure 5B).
dl922-947 impairs Atc-induced angiogenesis and 
monocyte chemotaxis in vitro via reduction of IL-8 
and ccl2
The remarkable reduction of IL-8 and CCL2 
secretion upon dl922-947 treatment prompted us to 
investigate its impact on the outcome of ATC virotherapy. 
IL-8 stimulates cancer cell proliferation, survival and 
invasion, and angiogenesis [38]. Treatment of ATC 
cells with IL-8 did not affect cell cycle progression 
(Supplementary Figure 6A), nor it increased cell survival 
of dl922-947-treated cells (Supplementary Figure 6B). 
Then, we analyzed the effects of dl922-947 on cell 
motility and angiogenesis using conditioned media (CM) 
of untreated and dl922-947-treated ATC cells. dl922-947 
CM reduced cell motility in an in vitro wound-healing 
assay (Figure 4A). The effect was reverted by the addition 
of recombinant IL-8 (Figure 4A). ATC-CM also had a 
significant pro-angiogenic activity that was impaired by 
the addition of an anti-IL-8 blocking antibody, as assessed 
by an in vitro angiogenesis assay (Figure 4B). Conversely, 
dl922-947-CM exhibited a reduced pro-angiogenic 
activity compared to CM of untreated cells (Figure 4B). 
The addition of recombinant IL-8 completely reverted this 
effect (Figure 4B). 
Finally, we investigated whether ATC-CM induce 
monocyte chemotaxis by producing the monocyte-
attracting chemokine CCL2. CM of untreated ATC cells 
induced monocyte chemotaxis in vitro (Figure 5). In 
accordance with dl922-947-mediated reduction of CCL2, 
dl922-947-CM exhibited a reduced chemotactic activity 
on monocytes (Figure 5). The effect was reverted by the 
addition of recombinant CCL2 (Figure 5).
dl922-947 treatment reduces angiogenesis and 
tAM density in an in vivo model of ATC
To validate our results in vivo, we established tumor 
xenografts in athymic mice using the ATC cell line 8505-c. 
This cell line was chosen because of its higher resistance 
to dl922-947 treatment. Mice were intratumorally injected 
with dl922-947 (5*107 pfu) twice per week for a total of 3 
weeks. All animals were sacrificed after 6 weeks from the 
beginning of treatment. dl922-947 treatment significantly 
reduced tumor volume already at 8 days and completely 
eradicated the tumors in 40% of mice after 2 weeks (Figure 
6A and Supplementary Figure 7). These animals remained 
tumor-free until the end of the experiment. In previous 
studies performed with a different ATC cell line we did 
not observe a significant effect of the virus within 8 days 
of treatment [26, 28, 29], and a complete tumor regression 
rarely occurred (Portella G., personal observations). These 
discrepancies can be explained by taking into account the 
higher viral dose used in the present study.
After 1 week of treatment, we observed decreased 
levels of IL-8 (Figure 6B-6C) that correlated with reduced 
expression of Cd31 mRNA (an endothelial cell marker) 
(Figure 6D) and tumor microvessel density (TMD) 
(Figure 6E-6F) after 3 weeks of treatment. CCL2 mRNA 
expression was also reduced after 1 week of treatment 
(Figure 7A). This effect was paralleled by a decrease in 
TAM density as shown by immunohistochemistry (Figure 
7B). Interestingly, dl922-947 treatment also induced a 
switch of TAM polarization toward a pro-inflammatory 
M1 phenotype, as assessed by increased expression of 
the M1 marker Nos2 (Figure 7C). Accordingly, we also 
observed increased Ifng mRNA levels (Figure 7D), a 
cytokine that induces Nos2 expression in macrophages 
[52]. No significant modulation of the M2-associated 
genes Ym1 and Arg1 was detected (Figure 7C).
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Figure 4: dl922-947 modulation of ATC cell motility and angiogenesis in vitro. A. In vitro wound-healing assay was used to 
assess ATC cell motility in two dimensions. 8505-c and BHT101-5 cell monolayers were scraped in a straight line to create a ‘‘scratch’’. 
Cells were then incubated with conditioned media (CM) obtained from 8505-c and BHT101-5 cells treated or not (CTRL) with dl922-947 
(5 and 1 pfu/cell, respectively). Recombinant IL-8 (10 ng/mL) was also added to CM obtained from dl922-947-treated cells. The distance 
traveled by the cells was determined by measuring the wound width at time 9 hours (for 8505-c cells) and time 6 (for BHT101-5 cells) and 
subtracting it from the wound width at time 0. The values obtained were then expressed as % migration, setting the gap width at time 0 as 
100%. One-way ANOVA and Tuckey post-test: *p<0.05; **p<0.01. b. HUVEC cells were incubated with CM obtained as indicated above. 
Tube formation was evaluated after 16 hours. Graphs display three different parameters: n° of meshes (n° of tubes), total area of meshes 
and n° of branching points. The results are the mean of three independent experiments ±SEM. One-way ANOVA and Tuckey post-test: 
*p<0.05; **p<0.01.
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Figure 5: dl922-947 modulation of monocyte chemotaxis in vitro. Monocytes onto the filters in the top compartment of the 
Boyden chamber. Conditioned media (CM) obtained from 8505-c and BHT101-5 cells treated or not (CTRL) with dl922-947 (5 and 1 
pfu/cell, respectively) were added into the lower chamber. Recombinant CCL-2 (10 ng/mL) was also added to CM obtained from dl922-
947-treated cells. After 2 hours filters cells that migrated through the filter were counted. The results are the mean of three independent 
experiments ±SEM. One-way ANOVA and Tuckey post-test: ***p<0.001.
Figure 6: In vivo effects of dl922-947 on IL-8 expression and angiogenesis. A. 6 week-old female CD1 athymic mice (15/group) 
were injected into the right flank with 8505-c cells (1*107 cells/0.2 mL). Two weeks after tumor injection, mice were treated intratumorally 
with dl922-947 (5*107 pfu) or its vehicle (CTRL) at day 0, 4, 8, 11 and 14 (day 0 = first injection of the virus). Tumor diameters were 
measured with calipers at day 0, 4, 8, 11, 14, 18 and 22 and tumor volume was calculated. Differences in the rate of tumor growth were 
assessed for each time point. Student’s t test: *p<0.05. b. Real-Time PCR analysis of IL8 mRNA levels in tumors excised at day 8 (5/group) 
treated as described above. Student’s t test: *p<0.05. c. Representative histological analysis of IL-8 expression in tumor samples excised 
at day 8 treated as described above. d. Real-Time PCR analysis of Cd31 mRNA levels in tumors excised at day 22 (3/group) treated as 
described above. Student’s t test: **p<0.01. e. Representative histological analysis of CD31 expression in tumor samples excised at day 22 
treated as described above. F. Quantification of tumor microvessel density (TMD) in tumor samples excised at day 22 treated as described 
above. TMD was determined as the percentage of CD31-positive area on total tumor area per field. Three randomly selected areas from 
three different tumors for each group were analyzed. Student’s t test: ***p<0.001.
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dIscussIon
Anaplastic thyroid carcinoma is one of the 
deadliest human malignancies, rapidly leading to trachea 
obstruction and death [17]. ATC is resistant to current 
available treatments and novel therapeutic strategies are 
needed. Preclinical studies have demonstrated that the 
oncolytic virus dl922-947 holds potential for the treatment 
of ATC. The main focus of these studies has been the 
direct cell killing activity of the virus and its ability to 
potentiate other treatments. Here, we demonstrate that 
dl922-947 treatment also affects tumor angiogenesis and 
macrophage density, two hallmarks of the pro-tumorigenic 
ATC microenvironment.
The development of a pro-tumorigenic 
microenvironment is a complex process, which also 
involves cytokine and chemokine production by cancer 
cells [53]. In particular, the production of IL-8 by ATC 
cells is involved in several aspects of tumorigenesis, 
namely induction of angiogenesis, epithelial-to-
mesenchymal transition and stemness [35, 37]. 
Therapeutic strategies aimed at targeting IL-8 could 
represent a promising approach for ATC management. Our 
results demonstrate that the treatment with the oncolytic 
virus dl922-947 reduces IL-8 production by ATC cells 
in vitro and in vivo. In addition, we show that ATC cells 
produce the monocyte-attracting chemokine CCL2, which 
is likewise reduced by dl922-947 treatment. We confirmed 
these results in the papillary thyroid cancer cell line TPC1. 
The production of IL-8 and CCL2 has been demonstrated 
for several cancer cell types [54]. Whether the modulation 
of these chemokines represents a general feature of dl922-
947 treatment or a thyroid-specific effect is unclear at 
present. 
The expression of IL8 and CCL2 genes is induced 
by the binding of NF-κB p65 to cis-regulatory elements 
in their promoters [44-46]. We demonstrate that dl922-
947 treatment decreases p65 binding to IL8 promoter 
in both ATC cell lines and TPC1 as well. We also show 
that dl922-947 reduces p65 binding to CCL2 promoter in 
8505-c and TPC1 cells, while no constitutive p65 binding 
was observed in BHT101-5 cells. Several additional 
transcription factors (e.g. AP-1 and Sp1) [45, 46] not 
assessed in our study have been involved in modulating 
CCL2 gene expression and likely compensate for the 
absence of p65 binding in BHT101-5 cells. Nevertheless, 
CCL2 reduction in BHT101-5 cells upon dl922-947 
treatment suggests a broad impact of the virus on several 
transcription factors.
The modulation of NF-κB activity by dl922-
947 may involve several and not mutually exclusive 
mechanisms. There are five NF-κB family members in 
mammals (RelA/p65, RelB, c-Rel, p50 and p52) that 
may combine in homodimers or heterodimers [55]. p65 is 
usually retained in the cytoplasm as a p65:p50 heterodimer 
Figure 7: In vivo effects of dl922-947 on tumor macrophage density and polarization. A. Real-Time PCR analysis of 
CCL2 mRNA levels in tumors excised at day 8 (5/group) treated as described in Figure 6A. Student’s t test: **p<0.01. b. Representative 
histological analysis of F4/80 expression in tumor samples excised at day 8 treated as described in Figure 6A. Red arrows indicate illustrative 
F4/80-positive cells (macrophages). c. Real-Time PCR analysis of mRNA levels of the M2 (Ym1, Arg1) and M1 (Nos2) markers in tumors 
excised at day 8 (5/group) treated as described in Figure 6A. Student’s t test: *p<0.05. d. Real-Time PCR analysis of Ifng mRNA levels in 
tumors excised at day 8 (5/group) treated as described in Figure 6A. Student’s t test: *p<0.05.
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due to its interaction with IκBα that masks the p65 nuclear 
localization signal while exposing a nuclear export signal. 
Phosphorylation and proteasomal degradation of IκBα 
induces the translocation of NF-κB dimers to the nucleus 
[55]. We demonstrate a direct interaction of the adenoviral 
protein E1A and its mutated form E1AΔ24 with p65 in 
8505-c cells, a mechanism reported to inhibit the NF-κB 
pathway in several adenovirus-infected cell lines [48]. 
Transfection of both E1A and E1AΔ24 reduces IL8 and 
CCL2 mRNA expression in 8505-c cells. These results 
were confirmed in TPC1 cells but were not observed in 
BHT101-5 cells. Accordingly, we could not demonstrate 
the binding of E1A and E1AΔ24 to p65 in the latter cell 
line. dl922-947 treatment reduces p65 nuclear localization 
in BHT101-5 cells, which likely accounts for the reduced 
p65 binding to IL8 promoter. Thus, it is likely that in this 
cell line dl922-947 interferes with one or more steps of 
p65 nuclear translocation/localization through a still 
uncovered mechanism. Taken together, our results indicate 
that dl922-947 interferes with the NF-κB pathway, which 
plays a prominent role in ATC pathogenesis [56]. Again, it 
will be relevant to assess whether this effect is specific for 
thyroid cancers or it is shared by other tumors that display 
an enhanced NF-κB activity (e.g. breast cancer, colorectal 
cancer) [57, 58].
In an effort to identify the functional significance 
of dl922-947-mediated IL-8 and CCL2 reduction, we 
found that dl922-947 treatment of ATC cells impairs IL-
8-induced angiogenesis and CCL2-induced monocyte 
chemotaxis in vitro. These findings were substantiated 
by in vivo results. Indeed, dl922-947 treatment of tumor 
xenografts established in athymic mice reduces IL8 
mRNA level after 1 week and Cd31 mRNA level and 
TMD after 3 weeks of treatment. These observations 
are in line with the anti-angiogenic effect of dl922-947 
observed in ATC xenografts established with FRO cells 
[29]. Although our results strongly suggest that the anti-
angiogenic activity of dl922-947 relies on the decreased 
production of IL-8 by ATC cells, we cannot exclude that 
the in vivo effects of dl922-947 treatment on TMD are 
triggered by additional mechanisms. Indeed, in unrelated 
tumor models, oncolytic adenoviruses exert an anti-
vascular activity through different mechanisms [59]. 
A replication-competent oncolytic adenovirus lacking 
E1B suppresses the production of the pro-angiogenic 
factor VEGF-A in pancreatic cancer cells by disrupting 
the interaction between the transcription factor HIF-1α 
and the transcriptional co-activator p300 [60]. Our data 
demonstrate that dl922-947 does not modulate VEGF-A 
secretion in ATC cells. The vasculature-disrupting activity 
of oncolytic adenoviruses may also rely on the production 
of anti-angiogenic cytokines by immune cells, namely 
IFNγ [61]. 
The prominent role of TAMs in cancer progression 
and modulation of therapeutic responsiveness has been 
established in several models [62-64]. Therapeutic 
strategies aimed at depleting TAMs or modulating their 
activity are being developed and tested in clinical trials. 
These approaches would be suitable for treating ATC 
since this tumor is markedly infiltrated by TAMs [31, 
32]. Treatment with wild type or E1A- or E3-deleted 
adenoviruses modulates macrophage infiltration in several 
tumor models [65]. Here we demonstrate that dl922-
947 treatment reduces the production of the monocyte-
attracting chemokine CCL2, human monocyte chemotaxis 
in vitro and TAM density in vivo. It is not possible to 
exclude that the reduced tumor vasculature in dl922-947-
treated tumors may contribute to decrease TAM density by 
reducing the recruitment of peripheral blood monocytes. 
Thus, dl922-947-mediated reduction of CCL2 and IL-8 
may have a synergistic effect on TAM depletion by 
reducing chemokine-induced monocyte recruitment and 
tumor vasculature.
TAM depletion in dl922-947-treated tumors is 
associated with increased expression of Nos2, a marker 
of pro-inflammatory M1 macrophages. Accordingly, we 
observed increased expression of Ifng mRNA (encoding 
the protein IFNγ) that may be responsible for the switch 
toward a macrophage M1 phenotype [52]. Several 
lymphocyte populations, namely NK cells, CD4 and CD8 
T lymphocytes produce IFNγ. Preliminary results suggest 
that dl922-947 treatment induces intratumoral recruitment 
of activated NK cells (Passaro C. and Borriello F., 
unpublished observations). However, our results were 
obtained using ATC xenografts established in athymic 
mice. This model lacks in T cell-mediated immunity and 
therefore does not completely recapitulate the lymphocyte-
mediated anti-tumor response elicited by virotherapy. 
Recently, mouse ATC cell lines have been established [66] 
that will allow the development of ATC allograft models 
in immunocompetent mice. It will be interesting to assess 
the effects of dl922-947 treatment in the context of a 
fully competent immune system since there is evidence 
that virotherapy induces a robust and long-lasting T cell-
mediated anti-tumor response [7-9].
In conclusion, we demonstrate that dl922-947 
treatment, along with its known role in inducing cell death, 
impacts on ATC microenvironment by modulating cancer-
cell intrinsic factors and the immune response. Our results 
may be helpful for refining ATC virotherapy in the context 
of cancer immunotherapy [67].
MAterIAls And Methods 
cells, adenoviruses, recombinant cytokines and 
blocking antibodies
Human thyroid carcinoma cell lines 8505-c 
(anaplastic), BHT101-5 (anaplastic) and TPC1 (papillary) 
have been described and authenticated elsewhere 
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[68]. dl922-947 (Δ24bpCR2E1A, ΔE3B) and the non-
replicating reporter adenovirus AdGFP (ΔE1) were 
expanded in the human embryonic kidney cell line HEK-
293, purified and stored as previously reported [69]. Δ19K 
was kindly provided by Dr Gunnel Halldén (Barts Cancer 
Institute, London, UK). Recombinant human IL-8, IFNβ 
and anti-IL-8 blocking antibody were purchased from 
PeproTech (London, UK). 
elIsA assay
1*104 8505-c, BHT101-5 or TPC1 cells were plated 
in 12-multiwell plates and treated as indicated. After 48 
hours of treatment, cytokine concentrations were measured 
in cell-free supernatants using commercially available 
ELISA kits for IL-8 (DY208, R&D Systems, Minneapolis, 
MN, USA) and CCL2 (88-7399-22, eBioscience, San 
Diego, CA, USA). IFNβ concentration was detected by 
sandwich ELISA using rabbit anti-human IFNβ (500-
P32B, PeproTech, London, UK) and biotinylated rabbit 
anti-human IFNβ (500-P32BBt, PeproTech, London, UK). 
When indicated, cytokine concentrations were normalized 
on total cellular protein content. Standard curves were 
generated with a Four Parametric Logistic curve fit and 
data were analysed using MyAssays Analysis Software 
Solutions (www.myassays.com).
rnA isolation and real-time Pcr
For in vitro experiments, 2*105 8505-c, BHT101-
5 or TPC1 cells were plated in 60mm dishes. After 48 
hours of treatment total, RNA was extracted using Trizol 
reagent (Invitrogen, Carlsberg, CA, USA) according to 
the manufacturer’s instructions. For in vivo experiments, 
tumors were excised at day 8 (week 1 of treatment) and 
day 22 (week 3 of treatment), homogenized and total 
RNA was extracted using Trizol reagent (Invitrogen, 
Carlsberg, CA, USA) according to the manufacturer’s 
instructions. 2 µg of total RNA were reverse-transcribed 
using Superscript III Reverse Transcriptase (Invitrogen, 
Carlsberg, CA, USA). Real-Time PCR was carried out 
using a CFX96 Real-Time System (Biorad, Hercules, 
CA, USA). Reactions were run in triplicate in three 
independent experiments. Specific primers were used 
to measure mRNA expression by Real-Time PCR. The 
list of primers is available as Supplementary Table 1. 
Expression data were normalized to the geometric mean 
of housekeeping gene GAPDH analyzed using the 2-ΔCT or 
2-ΔΔCT methods [70]. 
chromatin Immunoprecipitation (chIP) assay 
2*106 cells were seeded in 100mm dish and 24 
hours later treated with dl922-947 (5, 1 and 5 pfu/cell for 
8505-c, BHT101-5 and TPC1 cells, respectively). At 24 
hours post-infection (hpi) cells were washed with PBS 
and cross-linked using 1% formaldehyde for 15 min. The 
cross-linking reaction was stopped by the addition of 125 
mM glycine. Cells were washed twice in cold PBS, lysed 
in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-
HCl pH8.1, 1X protease inhibitor mixture) and sonicated 
five to nine times for 30 sec each at 18% maximum 
setting of the sonicator (Branson Sonifier, model 250) 
to achieve chromatin fragments ranging between 300 
and 800 bp in size. Immunoprecipitation was carried out 
overnight at 4°C with 2.5 µg of the appropriate antibody: 
p65 (sc-372X, Santa Cruz Biotechnology, Dallas, TX, 
USA) or normal rabbit IgG (17-684, Millipore, Billerica, 
MA, USA) (as negative control). Chromatin-antibody 
complexes were isolated using protein G/salmon sperm 
DNA (Millipore, Billerica, MA, USA) and sequentially 
washed for 5 min each in wash buffer I (0.1% SDS, 1% 
Triton X-100, 2mM EDTA, 150mM NaCl, 20mM Tris-
HCl, pH8.1), wash buffer II (wash buffer I with 500mM 
NaCl), wash buffer III (0.25M LiCl, 1% Nonidet P-40, 1% 
deoxycholate, 1mM EDTA, 10mM Tris-HCl, pH 8.1) and 
twice with TE buffer (10mM Tris-HCl, pH 7.5, 0.1mM 
EDTA). Input DNA (one-tenth of total lysates separated 
before immunoprecipitation) and immunoprecipitates 
were eluted by freshly prepared buffer (1% SDS, 0.1M 
NaHCO
3
) and overnight heated at 65°C to reverse 
formaldehyde cross-linking. DNA fragments were 
recovered by phenol/chloroform extraction and analyzed 
by Real-Time PCR with primers listed in Supplementary 
Materials. Relative fold change was assessed using the 
2-ΔΔCT method and normalized to input.
Protein extraction, cellular fractionation and 
western blot analysis
After the indicated treatments, attached and 
detached cells were harvested and protein lysates were 
prepared as previously described [24]. 20 µg of protein 
lysates were probed with the following antibodies: p65 
(sc-372X, 1:1000, Dallas, TX, Santa Cruz), Lamin A/C 
(sc-20681, 1:500, Santa Cruz, Dallas, TX, USA), α-tubulin 
(#T9026, 1:5000, Sigma-Aldrich, St. Louis, MO, USA), 
Adenovirus 2/5 E1A (sc-430, 1:500, Dallas, TX, Santa 
Cruz, USA). Cellular fractionation was performed using 
NE-PER™ Nuclear and Cytoplasmic Extraction Kit 
(Thermo Fisher Scientific, Waltham, MA, USA) following 
manufacturer’s instruction.
Cloning and transfection
The DNA sequences of wild type (E1Awt) and Δ24 
form of E1A (E1AΔ24) were amplified by polymerase 
chain reaction (PCR) using Long expand High-Fidelity 
DNA Polymerase (Roche, Basel, Swiss). The viral 
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genomic DNA from wild type adenovirus type 5 and 
dl922-947 were respectively used as templates. The 





The underlined sequences in both primer sequences 
correspond, respectively, to the HindIII and XhoI 
restriction sites, which are compatible with the multiple 
cloning sites on pcDNA3 expression vector. The PCR 
fragment and the pcDNA3 vector were then digested with 
the same enzymes to generate the same sticky ends. The 
digestion products of both the PCR fragments and the 
expression vector were ligated at 16°C for 16 hours in 
the presence of the ligation buffer and T4 DNA ligase. 
Ligated mixture was transformed into an appropriate 
bacteria strain DH5α. Transformed cells were selected 
on a LB plate containing 100 mg/mL ampicillin at 37°C 
for 16 hours. Positive transformants were inoculated into 
LB broth containing 100 mg/mL ampicilin for plasmids 
propagation. Plasmids were isolated and the presence 
of the inserts was determined by polymerase chain 
reaction (PCR) and restriction enzyme digestion. Inserts 
were sequenced before proceeding with transfection. 
pcDNA3 plasmid containing p65 coding sequence was 
kindly provided by Paola Ungaro (University of Naples 
Federico II, Naples, Italy). 8505-c, BHT101-5 and TPC1 
cells were seeded in 60mm dish. When cells reached 80% 
of confluence, 1 μg of plasmidic DNA from p65, E1Awt 
and E1AΔ24 plasmids was transfected as indicated 
using Lipofectamine® 3000 following manufacturer’s 
instruction. (Life Technologies, Carlsbad, CA, USA). 
co-immunoprecipitation
8505-c and BHT101-5 cells were transfected with 
E1Awt or E1AΔ24 alone or co-transfected with p65. 
32 hours after transfection total proteins were extracted 
using Buffer X (50 mM Tris pH 8.8, 250 mM NaCl, 
1% NP-40, 2 mM, EDTA, 2 mg/mL BSA) and 500 ng 
of total lysates were used for immunoprecipitation. 
Immunoprecipitation was carried out overnight at 4°C 
with 2 µg of the anti-Adenovirus 2/5 E1A antibody (sc-
430, 1:500, Santa Cruz Biotechnology, Dallas, TX, USA). 
Protein-antibody complexes were isolated using protein A 
(Millipore, Billerica, MA, USA) and sequentially washed 
with NETN buffer (150 mM NaCl, 1 mM EDTA, 20 mM 
tris-HCl pH 8, 0.2 % NP-40). Buffers were supplemented 
with 1X proteases and phosphatases inhibitor mixture. 
The binding of E1Awt or E1AΔ24 to p65 was assessed by 
western blot using an anti-p65 antibody (sc-372X, Santa 
Cruz Biotechnology, Dallas, TX, USA).
In vitro wound healing assay
8505-c and BHT101-5 cells were plated overnight 
to achieve a subconfluent cell layer in 60mm plates. 
Cell monolayer was scraped in a straight line to create 
a ‘‘scratch’’ with a p10 pipet tip. Debris were removed 
and the edge of the scratch smoothed by washing the cells 
once with PBS. Cells were then incubated with 3 ml of 
conditioned media (CM) to perform the in vitro scratch 
assay. The distance traveled by the cells was determined 
by measuring the wound width at time 9 or 6 hours (for 
8505-c and BHT101-5 cells, respectively) and subtracting 
it from the wound width at time 0. The values obtained 
were then expressed as % of migration, setting the gap 
width at time 0 as 100%. CM were collected from 8505-c 
and BHT101-5 cells treated or not (CTRL) for 48h with 
dl922-947 and UV irradiated (seven cycles of 125J UV 
light) to inactivate the virus [71]. 
Endothelial tube formation assay (in vitro 
angiogenesis)
1*104 8505-c or BHT101-5 cells were plated in 
12-multiwell plates and treated as indicated. After 48 
hours of treatment, conditioned media were collected as 
described above. The angiogenesis assay was performed 
using the Endothelial tube formation assay (in vitro 
angiogenesis) kit (Life Technologies, Carlsbad, CA, USA) 
following manufacturer’s instruction. Three different 
angiogenic parameters were evaluated (number of meshes, 
total area of meshes and number of branching point) as 
previously described [72].
In vitro chemotaxis assay 
Peripheral blood from healthy donors was layered 
onto Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, 
USA) and centrifuged at 400g for 20 min. Mononuclear 
cells were collected at the interface and monocytes 
were further purified with CD14 Microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). Chemotaxis 
was performed in a 48-microwell chemotaxis chamber 
(Costar-NucleporeTM, Milan, Italy), using a 5 μm pore-size 
polyvinylpyrrolidone-free polycarbonate filter (Sigma-
Aldrich, St. Louis, MO, USA) which divides each well 
into two compartments. 27 μl of CM obtained as described 
above were added to the lower compartment. DMEM 
with 0.1% BSA was used as negative control to evaluate 
background migration. The upper compartment was filled 
with 50 μl of monocyte suspension (2*106 cells/ml in 
DMEM with 0.1% BSA). The chamber was incubated at 
37°C in a 5% CO
2
 humidified atmosphere for 120 min. 
The filter was then removed and cells were fixed with 
absolute ethanol and stained with Differential Quik Stain 
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Kit (Polysciences, Warrington, PA, USA). Cells that had 
not migrated were removed from the upper surface of the 
filter. Migrated cells were counted in nine microscopic 
fields per well.
Mice and ATC xenograft model
CD-1® athymic mice were obtained from Charles 
River (Wilmington, MA, USA) and maintained at 
the Department of Molecular Medicine and Medical 
Biotechnologies Animal Facility (University of Naples 
Federico II, Naples, Italy). All experiments were 
carried out using 6-week-old females. To initiate tumor 
xenografts, 8505-c cells in exponential phase were 
prepared at a concentration of 1*107cells/ml in 0.2 ml of 
DMEM medium. Cell suspension was injected into the 
right flank of 30 animals. Tumor diameters were measured 
with calipers and tumor volume (V) was calculated by the 
formula for a rotational ellipsoid: V=A*B2/2 (A, axial 
diameter; B, rotational diameter). Mice weights were 
weekly monitored. Twenty days post-injection mice with 
similar tumor size were randomized into two groups (15 
animals/group): untreated and treated with dl922–947. A 
high viral dose (5*107 pfu) was administered twice per 
week by intratumoral injection to avoid any first-pass 
effect for a total of three weeks [26, 69, 27]. All animal 
experiments were conducted in accordance with accepted 
standards of animal care and the Italian regulations for 
the welfare of animals used in studies of experimental 
neoplasia. The study was approved by our institutional 
committee on animal care.
Immunohistochemistry, tumor microvessel and 
tAM density measurement
Formalin fixed, paraffin embedded 4 μm sections of 
tumors were processed as already described [73]. Antigen 
retrieval was performed in 1 mM EDTA buffer pH 8 and 
primary antibodies were left ON at 4°C. The following 
antibodies were used: CD31 (Ab28364, dilution 1:50, 
Abcam, Cambridge, UK), F4/80 (12506, dilution 1:50, 
Novus, Littleton, CO, USA) and IL-8 (Ab106350, dilution 
1:1000, Abcam, Cambridge, UK). To calculate the tumor 
microvessel density (TMD), CD31-positive area and total 
tumor area per field from was measured using ImageJ 
software. TMD was then determined as a percentage of 
CD31-positive area per field. Three randomly selected 
areas from three different tumors were analyzed.
statistical analysis
Statistical analysis was performed with Prism 5 
(GraphPad Software). p values were calculated with paired 
t test or repeated measure one-way ANOVA corrected for 
multiple comparisons unless otherwise indicated. p < 0.05 
was considered significant.
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